Condition: High-risk Non-muscle Invasive Bladder Cancer · Sponsor: RemeGen Co., Ltd.
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2
This description comes directly from the study's public registry record.
Hong Luo · +8610-58075763 · hong.luo@remegen.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital,SunYat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Tongji Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Cancer hospital | Changsha, Hunan, China | Recruiting |
| The first affiliated hospital with nanjing medical universtity | Nanjing, Jiangsu, China | Not Yet Recruiting |
| West China Hospital | Chengdu, Sichuan, China | Not Yet Recruiting |
| Tianjin Medical University Second Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06378242